Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro
about
sameAs
Structure-activity relationships and mode of action of 5-mercapto-substituted oligo- and polynucleotides as antitemplates inhibiting replication of human immunodeficiency virus type 1Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidineActivities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidineRelationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.Antiretroviral therapy: reverse transcriptase inhibition.Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.Antiviral therapy for human immunodeficiency virus infectionsPenetration of foscarnet into cerebrospinal fluid of AIDS patients.Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudineZidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053)Emerging therapies for herpes viral infections (types 1 - 8).Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.Effect of (r)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) and AZT-lipid-PFA on human herpesvirus-6B infected cellsSynthesis and antiviral evaluation of SATE-foscarnet prodrugs and new foscarnet-AZT conjugates.Natural Plant Alkaloid (Emetine) Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity.In vitro anti-HIV-1 activity of sn-2-substituted 1-O-octadecyl-sn-glycero-3-phosphonoformate analogues and synergy with zidovudine.Safety of alternating ganciclovir and foscarnet maintenance therapy in human immunodeficiency virus (HIV)-related cytomegalovirus infections. An open-labeled pilot study.Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.Trichothecene synergism, additivity, and antagonism: the significance of the maximally quiescent ratio.Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.Selective Excision of Chain-terminating Nucleotides by HIV-1 Reverse Transcriptase with Phosphonoformate as Substrate
P2860
Q28319929-6FC3F56C-4F0B-4B88-8CE1-F03697FBC9AFQ28324208-73567BA3-6930-4125-8E0F-6A40D2587638Q28335917-410DCEBD-DE0C-4B5D-BC2B-599CF854138EQ28378983-286CCD8F-C395-4962-9E0F-54FFCE5B0FDCQ34996622-987F0475-9F68-4F4C-824B-08F18AD0A3D7Q35118174-23615C6D-24BB-4F9F-AE7A-5350F23F52CDQ35322871-8985A312-0461-42D8-8E1E-33F342F2CA24Q35325810-C0A901DA-E608-422C-BDF7-CEA63D46B73EQ35366050-6DD1797B-F0FA-410A-85C3-725773F95732Q35818751-4B065148-3E18-4CEA-9D1C-616D6F45177BQ35840864-09042BD7-619C-420E-94B6-B79C4ACAE0FAQ35870930-5CE7E2E0-8622-4E80-8DDB-47D3F2C30552Q35894405-E42497A2-0728-431D-B336-7E26365207EBQ35967376-F7A52202-F021-4C00-859E-75836C09C383Q37446675-F0856CE4-A786-4C46-950C-A8A41A053847Q37561897-B3B6B2FC-4E67-4A4E-B2E4-B8785BE1ECC5Q40983982-C6BABEAB-72F2-46D5-9B9C-584F977D4606Q41140055-5C29290A-3757-4115-B390-CBF4323B1387Q41748484-B727970B-B00D-4D93-AD77-C7E8082C0E45Q45778365-3F1C7333-DF3F-4D79-B1AD-AC88C2B1B389Q46393134-E4416B16-5B39-4473-A674-238443487E84Q52234590-F3905BD4-D0D4-4328-AA92-A4A8FC434907Q54257052-FAB350B3-30CB-43B3-B466-B45F56B8F315Q57418400-3D81C3EE-94F8-484C-9ABA-E24B5BF40F52
P2860
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro
description
1989 nî lūn-bûn
@nan
1989 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Combinations of 3'-azido-3'-de ...... galovirus replication in vitro
@ast
Combinations of 3'-azido-3'-de ...... galovirus replication in vitro
@en
Combinations of 3'-azido-3'-de ...... galovirus replication in vitro
@nl
type
label
Combinations of 3'-azido-3'-de ...... galovirus replication in vitro
@ast
Combinations of 3'-azido-3'-de ...... galovirus replication in vitro
@en
Combinations of 3'-azido-3'-de ...... galovirus replication in vitro
@nl
prefLabel
Combinations of 3'-azido-3'-de ...... galovirus replication in vitro
@ast
Combinations of 3'-azido-3'-de ...... galovirus replication in vitro
@en
Combinations of 3'-azido-3'-de ...... galovirus replication in vitro
@nl
P2860
P356
P1476
Combinations of 3'-azido-3'-de ...... galovirus replication in vitro
@en
P2093
B F Eriksson
R F Schinazi
P2860
P356
10.1128/AAC.33.5.663
P407
P577
1989-05-01T00:00:00Z